JAK1 and rheumatoid arthritis: Tofacitinib (JAK1, 2, and 3 inhibitor [44]) suppresses OSM-induced JAK/STAT signalling in FLSs from patients with RA; OSM is a pleiotropic cytokine implicated in the progression of RA [34,45].